Potential molecular mechanisms of Erlongjiaonang action in idiopathic sudden hearing loss: A network pharmacology and molecular docking analyses.
Erlongjiaonang
ISHL
TCM
bioinformatics
gene targets
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
12
2022
accepted:
01
03
2023
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Idiopathic sudden hearing loss (ISHL) is characterized by sudden unexplainable and unilateral hearing loss as a clinically emergent symptom. The use of the herb Erlongjiaonang (ELJN) in traditional Chinese medicine is known to effectively control and cure ISHL. This study explored the underlying molecular mechanisms using network pharmacology and molecular docking analyses. The Traditional Chinese Medicine System Pharmacological database and the Swiss Target Prediction database were searched for the identification of ELJN constituents and potential gene targets, respectively, while ISHL-related gene abnormality was assessed using the Online Mendelian Inheritance in Man and Gene Card databases. The interaction of ELJN gene targets with ISHL genes was obtained after these databases were cross-screened, and a drug component-intersecting target network was constructed, and the gene ontology (GO) terms, Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction networks were analyzed. Cytoscape software tools were used to map the active components-crossover target-signaling pathway network and screened targets were then validated by establishing molecular docking with the corresponding components. Erlongjiaonang contains 85 components and 250 corresponding gene targets, while ISHL has 714 disease-related targets, resulting in 66 cross-targets. The bioinformatical analyses revealed these 66 cross-targets, including isorhamnetin and formononetin on NOS3 expression, baicalein on AKT1 activity, and kaempferol and quercetin on NOS3 and AKT1 activity, as potential ELJN-induced anti-ISHL targets. This study uncovered potential ELJN gene targets and molecular signaling pathways in the control of ISHL, providing a molecular basis for further investigation of the anti-ISHL activity of ELJN.
Sections du résumé
Background
UNASSIGNED
Idiopathic sudden hearing loss (ISHL) is characterized by sudden unexplainable and unilateral hearing loss as a clinically emergent symptom. The use of the herb Erlongjiaonang (ELJN) in traditional Chinese medicine is known to effectively control and cure ISHL. This study explored the underlying molecular mechanisms using network pharmacology and molecular docking analyses.
Method
UNASSIGNED
The Traditional Chinese Medicine System Pharmacological database and the Swiss Target Prediction database were searched for the identification of ELJN constituents and potential gene targets, respectively, while ISHL-related gene abnormality was assessed using the Online Mendelian Inheritance in Man and Gene Card databases. The interaction of ELJN gene targets with ISHL genes was obtained after these databases were cross-screened, and a drug component-intersecting target network was constructed, and the gene ontology (GO) terms, Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction networks were analyzed. Cytoscape software tools were used to map the active components-crossover target-signaling pathway network and screened targets were then validated by establishing molecular docking with the corresponding components.
Result
UNASSIGNED
Erlongjiaonang contains 85 components and 250 corresponding gene targets, while ISHL has 714 disease-related targets, resulting in 66 cross-targets. The bioinformatical analyses revealed these 66 cross-targets, including isorhamnetin and formononetin on NOS3 expression, baicalein on AKT1 activity, and kaempferol and quercetin on NOS3 and AKT1 activity, as potential ELJN-induced anti-ISHL targets.
Conclusion
UNASSIGNED
This study uncovered potential ELJN gene targets and molecular signaling pathways in the control of ISHL, providing a molecular basis for further investigation of the anti-ISHL activity of ELJN.
Identifiants
pubmed: 37064204
doi: 10.3389/fneur.2023.1121738
pmc: PMC10098218
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1121738Informations de copyright
Copyright © 2023 Zhao, Wang, Xu, Li, Song, Qiu, Cui, Song, Yang and Sun.
Déclaration de conflit d'intérêts
The authors declare that this research was conducted in the absence of any commercial or financial support that could be considered a conflict of interest.
Références
Am J Hum Genet. 2007 Apr;80(4):588-604
pubmed: 17357067
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395
pubmed: 33151290
Otolaryngol Head Neck Surg. 2019 Aug;161(1_suppl):S1-S45
pubmed: 31369359
Biomed Pharmacother. 2022 Sep;153:113295
pubmed: 35724507
Molecules. 2017 Jan 29;22(2):
pubmed: 28146071
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Brain Res. 2021 Nov 1;1770:147626
pubmed: 34418356
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Acta Pharmacol Sin. 2021 May;42(5):701-714
pubmed: 32796955
J Mol Biol. 2021 May 28;433(11):166704
pubmed: 33186584
Biomed Pharmacother. 2021 Aug;140:111729
pubmed: 34044274
J Immunol. 2017 Feb 1;198(3):1006-1014
pubmed: 28115590
Biomed Pharmacother. 2017 Nov;95:1021-1032
pubmed: 28922719
Phytother Res. 2021 Aug;35(8):4442-4455
pubmed: 34008261
Audiol Neurootol. 2021;26(1):45-52
pubmed: 32668428
Int J Mol Sci. 2021 Nov 03;22(21):
pubmed: 34769369
Eur J Med Chem. 2016 May 23;114:24-32
pubmed: 26974372
Biochem Biophys Res Commun. 2018 Sep 5;503(2):665-670
pubmed: 29908183
Front Pharmacol. 2022 Mar 07;12:791269
pubmed: 35342388
Inflammation. 2020 Aug;43(4):1337-1350
pubmed: 32180078
ACS Med Chem Lett. 2019 Apr 24;10(6):1002-1006
pubmed: 31223462
Front Pharmacol. 2021 Nov 23;12:719267
pubmed: 34887749
Free Radic Biol Med. 2010 Aug 1;49(3):307-16
pubmed: 20388537
Food Chem. 2021 Oct 15;359:129975
pubmed: 33962193
Life Sci. 2020 Oct 15;259:118183
pubmed: 32781058
Theranostics. 2020 Jan 1;10(3):1090-1106
pubmed: 31938053
Nucleic Acids Res. 2020 Jan 8;48(D1):D1031-D1041
pubmed: 31691823
Acta Otolaryngol. 2017;137(sup565):S8-S16
pubmed: 28394652
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Chin J Integr Med. 2020 Jan;26(1):72-80
pubmed: 30941682
Gene. 2016 Jan 10;575(2 Pt 3):584-99
pubmed: 26428312
J Agric Food Chem. 2018 Feb 7;66(5):1197-1205
pubmed: 29323924
Pestic Biochem Physiol. 2018 Nov;152:29-37
pubmed: 30497708
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W32-8
pubmed: 24792161
Spectrochim Acta A Mol Biomol Spectrosc. 2021 May 15;253:119605
pubmed: 33667888
Protein Sci. 2021 Jan;30(1):31-43
pubmed: 32808340
Biochem J. 2018 Apr 5;475(7):1253-1265
pubmed: 29523748
Biomed Pharmacother. 2020 Aug;128:110301
pubmed: 32502837
Front Cell Dev Biol. 2020 Sep 29;8:578197
pubmed: 33117805
Phytother Res. 2020 May;34(5):911-923
pubmed: 31829475
Biomed Pharmacother. 2018 Jul;103:800-811
pubmed: 29684859
Front Immunol. 2021 Jun 23;12:689044
pubmed: 34248976
Hear Res. 2022 Sep 1;422:108565
pubmed: 35816890
Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210
pubmed: 31369349
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
J Agric Food Chem. 2007 Nov 28;55(24):9969-76
pubmed: 17973448
Food Chem. 2021 Jan 1;334:127508
pubmed: 32711265
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2895–2904
pubmed: 27168365
Otol Neurotol. 2013 Dec;34(9):1586-9
pubmed: 24232060
Science. 1999 Nov 19;286(5444):1583-7
pubmed: 10567269